An observational study in Neoplasm, sponsored by Assistance Publique - Hôpitaux de Paris. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-27.
Sponsored by Assistance Publique - Hôpitaux de Paris · Observational
The purpose of this observational study is to evaluate the benefits of a pharmacist integration in an oncology ambulatory center, to prevent drug related problems (in particular drug drug interactions) at antitumor treatment initiation.
The hypothesis of this work is that a drug drug interaction will be observed in 30% of cancer patients and will have a major clinical impact in 1% of the cases. The primary endpoint is the prevalence of pharmacist interventions among patients who are going to receive an oral targeted therapy or cancer chemotherapy or immunotherapy
The purpose of this observational study is to evaluate the benefits of a pharmacist integration in an oncology ambulatory center, to prevent drug related problems (in particular drug drug interactions) at antitumor treatment initiation.
The hypothesis of this work is that a drug drug interaction will be observed in 30% of cancer patients and will have a major clinical impact in 1% of the cases.
The primary endpoint is the prevalence of pharmacist interventions among cancer patients who are going to receive an oral targeted therapy (140 patients) or cancer chemotherapy or immunotherapy (300 patients).
Pharmacist interventions will be classified according to the SFPC (société française de pharmacie Clinique) classification.
The secondary endpoints are
9,365 studies on the registry are indexed under Neoplasms; 2,489 are open to participants now.
This study's enrollment of 440 is above the median of 204 across 1,683 observational studies indexed under Neoplasms.
Browse Neoplasms studies →Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,505 studies on the registry; 1,006 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Cancer patients in outpatient setting, treated in two Paris hospitals
Exclusion Criteria:
Prevalence of Pharmacist intervention
Percentage of patients whom antitumora treatment or usual treatment has been changed by the pharmacist intervention
Time frame: up to 1 week from date of inclusion
Detection of Drug -drug interactions
Number of drug drug interactions detected
Time frame: up to 1 week from date of inclusion
Clinical gradation of drug drug interactions
Gradation by an independent experts comity of the clinical impact of prevented drug drug interaction
Time frame: One year
Cost of the pharmacist intervention by avoided clinical consequence
Cost evaluation of pharmacist for analysis and medication review with patient by avoided interaction
Time frame: One year
Potential cost of the avoided clinical consequences
Treatment cost of avoided clinical consequences , balanced with the probability of occurrence
Time frame: One year
Adherence evaluation with oral cancer targeted therapy by therapeutic drug monitoring
Patients with plasma drug concentration below the 10th percentile will be classified as nonadherent patients
Time frame: day 15, 30 and 6 months after oral therapy initiation
Adherence evaluation with oral cancer targeted therapy by the 6 item-Girerd Scale
Patients with a Girerd score greater than or equal to 3 will be classified as nonadherent patients
Time frame: day 15, 30 and 6 months after oral therapy initiation
Adherence evaluation with oral cancer targeted therapy by pill count
Pill counts will be used to calculate the percent of total prescribed dose taken to prescribed during the 90-day period
Time frame: 6 months after oral therapy initiation
Plan to share: No
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique - Hôpitaux de Paris